Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT - PEG-Intron and Rebetol for HCV Recurrence After Liver Transplant
NCT00378599Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2006
- Primary completion
- Jul 2009
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
01
Overview
A Phase 3 trial of peginterferon alfa-2b, ribavirin in hepatitis C virus infection, sponsored by Merck & Co.. Started May 2006; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT00378599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378599.